Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
The Pharma Letter5d
EC expands use of CAR T cell therapy Breyanzi
The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
PR Newswire11d
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...
PMLive5d
Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma
Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...
Yahoo Finance11d
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...
DelveInsight Business Research, LLP: BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
Bristol Myers announces EC approval of Breyanzi
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...